Capecitabine and hand–foot syndrome

Bibliography

• Xeloda (capecitabine) [package insert]: Nutley, NJ: Roche Pharmaceuticals; April 2006
   Google Scholar
• Saif MW, Elfiky AA. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol 2007;5:337-43
   PubMedGoogle Scholar
• Meta-Analysis Group In Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998;10:3537-41
   Google Scholar
• Blum JL, Jones SE, Buzdar AU, Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93
   PubMed Web of Science ®Google Scholar
• Gordon KB, Tajuddin A, Guitart J, Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-73
   PubMed Web of Science ®Google Scholar
• de Vries EG, Greidanus J, Mulder NH, A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 1987;5:1445-51
   PubMed Web of Science ®Google Scholar
• Zimmerman GC, Keeling JH, Burris HA, Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995;131:202-6
   PubMed Web of Science ®Google Scholar
• Beldner M, Jacobson M, Burges GE, Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib. Oncologist 2007;12:1178-82
   PubMed Web of Science ®Google Scholar
• Lacouture ME, Wu S, Robert C, Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11
   PubMed Web of Science ®Google Scholar
• Chau I, Norman AR, Cunningham D, A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005;16:549-57
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J, Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol 2007;25:102-9
   PubMed Web of Science ®Google Scholar
• Scheithauer W, McKendrick J, Begbie S, X-ACT Study Group. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2003;14:1735-43
   PubMed Web of Science ®Google Scholar
• Twelves C, Wong A, Nowacki MP, Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E, Capecitabine Colorectal Cancer Study Group. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-75
   PubMed Web of Science ®Google Scholar
• Douillard JY, Hoff PM, Skillings JR, Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-16
   PubMed Web of Science ®Google Scholar
• Carmichael J, Popiela T, Radstone D, Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-27
   PubMed Web of Science ®Google Scholar
• Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002;20:3-10
   PubMed Web of Science ®Google Scholar
• Lin E, Morris JS, Ayers GD. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. Oncology (Williston Park) 2002;16(12 Suppl 14):31-7
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Blum J. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine. Oncology (Williston Park) 2004;18:1161-8, 1173
   PubMed Web of Science ®Google Scholar
• Walker IR, Wilson WE, Sauder DN, Cytarabine-induced palmar-plantar erythema. Arch Dermatol 1985;121:1240-1
   PubMed Web of Science ®Google Scholar
• Silver FS, Espinoza LR, Hartmann RC. Acral erythema and hydroxyurea. Ann Intern Med 1983;98(5 pt 1):675
   PubMed Web of Science ®Google Scholar
• Vassallo C, Passamonti F, Merante S, Muco-cutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001;26:141-8
   PubMed Web of Science ®Google Scholar
• Fukamachi S, Nakamura M, Tokura Y. Cisplatin-induced acral erythema. Eur J Dermatol 2009;19:171-2
   PubMed Web of Science ®Google Scholar
• Pagliuca A, Kaczmarski R, Mufti GJ. Palmar-plantar erythema associated with combination chemotherapy. Postgrad Med J 1990;66:242-3
   PubMed Web of Science ®Google Scholar
• Feizy V, Namazi MR, Barikbin B, Ehsani A. Methotrexate-induced acral erythema with bullous reaction. Dermatol Online J 2003;9:14
   PubMedGoogle Scholar
• Hoff PM, Valero V, Ibrahim N, Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998;82:965-9
   PubMed Web of Science ®Google Scholar
• Scotte F, Banu E, Medioni J, Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 2008;112:1625-31
   PubMed Web of Science ®Google Scholar
• Giovannini M, Gregorc V, Belli C, Clinical significance of skin toxicity due to EGFR-targeted therapies. J Oncol 2009;2009:849051
   PubMedGoogle Scholar
• Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 2009;77:257-71
   PubMed Web of Science ®Google Scholar
• Lassere Y, Hoff P. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nurs 2004;8(Suppl 1):S31-40
   PubMedGoogle Scholar
• Saif MW, Juneja V, Black G, Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Support Cancer Ther 2007;4:211-18
   PubMedGoogle Scholar
• Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin Colorectal Cancer 2006;6:219-23
   PubMed Web of Science ®Google Scholar
• Saif MW, Sandoval A. Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? Cutan Ocul Toxicol 2008;27:311-15
   PubMed Web of Science ®Google Scholar
• Narasimhan P, Narasimhan S, Hitti IF, Rachita M. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature. Cutis 2004;73:101-6
   PubMed Web of Science ®Google Scholar
• Vickers MM, Easaw JC. Palmar-plantar hyperpigmentation with capecitabine in adjuvant colon cancer. J Gastrointest Cancer 2008;39:141-3
   PubMedGoogle Scholar
• Mattison LK, Fourie J, Desmond RA, Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5
   PubMed Web of Science ®Google Scholar
• Milano G, Etienne-Grimaldi MC, Mari M, Candidate mechanisms for capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;66:88-95
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res 2008;14:8-13
   PubMed Web of Science ®Google Scholar
• Asgari MM, Haggerty JG, McNiff JM, Expression and localization of thymidine phosphorylase/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 1999;26:287-94
   PubMed Web of Science ®Google Scholar
• Fischel JL, Formento P, Ciccolini J, Lack of contribution of dihydrofluorouracil and alpha-fluoro-beta-alanine to the cytotoxicity of 5′-deoxy-5-fluorouridine on human keratinocytes. Anticancer Drugs 2004;15:969-74
   PubMed Web of Science ®Google Scholar
• Temmink OH, de Bruin M, Turksma AW, Activity and substrate specificity of pyrimidine phosphorylases and their role in fluoropyrimidine sensitivity in colon cancer cell lines. Int J Biochem Cell Biol 2007;39:565-75
   PubMed Web of Science ®Google Scholar
• Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clin Colorectal Cancer 2006;5:359-62
   PubMed Web of Science ®Google Scholar
• Yamashita K, Yada H, Ariyoshi T. Neurotoxic effects of alpha-fluoro-beta-alanine (FBAL) and fluoroacetic acid (FA) on dogs. J Toxicol Sci 2004;29:155-66
   PubMedGoogle Scholar
• Okeda R, Shibutani M, Matsuo T, Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine. Acta Neuropathol 1990;81:66-73
   PubMed Web of Science ®Google Scholar
• Mrozek-Orlowski ME, Frye DK, Sanborn HM. Capecitabine: nursing implications of a new oral chemotherapeutic agent. Oncol Nurs Forum 1999;26:753-62
   PubMedGoogle Scholar
• Eda H, Fujimoto K, Watanabe S, Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 1993;32:333-8
   PubMed Web of Science ®Google Scholar
• Hu ZP, Yang XX, Chan SY, St. John's wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicol Appl Pharmacol 2006;216:225-37
   PubMed Web of Science ®Google Scholar
• Xue H, Field CJ, Sawyer MB, Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy. Br J Cancer 2009;100:1581-8
   PubMed Web of Science ®Google Scholar
• Melo ML, Brito GA, Soares RC, Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 2008;61:775-84
   PubMed Web of Science ®Google Scholar
• Cao S, Black JD, Troutt AB, Rustum YM. Interleukin 15 offers selective protection from irinotecan-induced intestinal toxicity in a preclinical animal model. Cancer Res 1998;58:3270-4
   PubMed Web of Science ®Google Scholar
• Disel U, Gurkut O, Abali H, Unilateral hand-foot syndrome: an extraordinary side effect of capecitabine. Cutan Ocul Toxicol 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Lacouture ME. Dermatologic toxicities associated with targeted therapies. Cancer management: a multidisciplinary approach. 11 edition. 2008; 15 May 2009. Available from: http://www.cancernetwork.com/cancer-management-11/coloratlas3/article/10165/1414174#
   Google Scholar
• Lopez AM, Wallace L, Dorr RT, Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol 1999;44:303-6
   PubMed Web of Science ®Google Scholar
• Bertelli G, Gozza A, Forno GB, Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13:2851-5
   PubMed Web of Science ®Google Scholar
• Fabian CJ, Molina R, Slavik M, Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63
   PubMed Web of Science ®Google Scholar
• Mortimer JE, Anderson I. Weekly fluorouracil and high-dose leucovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990;26:449-52
   PubMed Web of Science ®Google Scholar
• Saif MW, Eloubeidi MA, Russo S, Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005;23:8679-87
   PubMed Web of Science ®Google Scholar
• Yoshimoto N, Yamashita T, Fujita T, Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer. Breast Cancer 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kang YK, Lee SS, Yoon DH, Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 2010;28(24):3824-9
   PubMed Web of Science ®Google Scholar
• Kohne CH, De Greve J, Hartmann JT, Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol 2008;19:920-6
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007;25:4779-86
   PubMed Web of Science ®Google Scholar
• Kingsley EC. 5-Fluorouracil dermatitis prophylaxis with a nicotine patch. Ann Intern Med 1994;120:813
   PubMed Web of Science ®Google Scholar
• Cunningham D, Starling N, Rao S, Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46
   PubMed Web of Science ®Google Scholar
• Kang YK, Kang WK, Shin DB, Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20(4):666-73
   PubMed Web of Science ®Google Scholar
• Okines AF, Norman AR, McCloud P, Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20(9):1529-34
   PubMed Web of Science ®Google Scholar